We look forward to drawing on his expertise as we continue to make strides in developing RGLS8429, as well as our research programs." "Moh brings over 20 years of drug discovery and development experience to the company and we believe his background working specifically with oligonucleotides makes him uniquely qualified for the position. "We are excited to welcome Moh to the Regulus team," said Denis Drygin, Chief Scientific Officer of Regulus. Ahmadian will assist in managing research and development of the Company's drug candidates, including RGLS8429, which is being developed for patients with autosomal dominant polycystic kidney disease (ADPKD), and will add significant expertise to Regulus' existing scientific talent. 3, 2021 /PRNewswire/ - Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development.
0 kommentar(er)
